Predict your next investment

Corporation
jw-pharma.co.kr

See what CB Insights has to offer

Investments

1

Partners & Customers

3

About JW Pharmaceutical

JW Pharmaceutical strives to develop a variety of products for the concepts of wellbeing, patients and quality of life such as a premium hair dye "Chnagpo(n)" and low-protein, low-salt patients' JW's relief food for kidney disease patients. The company also produces generic medicines and healthcare products that can be easily purchased for the health and well-being of the family, such as the 28-year-old cold medicine "Hwacol", the care band for injury "Himom", and the series of premium eyes drop "Frenz Eye Drop".

JW Pharmaceutical Headquarter Location

2477, Nambusunhwan-ro

Seoul, 137-864,

South Korea

+82-2-840-6777

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest JW Pharmaceutical News

Actemra can’t replace Regkirona to treat mild Covid-19: MFDS

Mar 16, 2022

Actemra can’t replace Regkirona to treat mild Covid-19: MFDS 바로가기 기자명 Kim Chan-hyuk The government granted emergency authorization for Actemra (ingredient: tocilizumab) to treat Covid-19 infection. However, the Ministry of Food and Drug Safety (MFDS) said Actemra is indicated for critically ill Covid-19 patients and will not replace Celltrion’s Regkirona (regdanvimab), which is used for mild and moderate Covid-19 infection. The regulator authorized the emergency use of Actemra for the treatment of seriously ill Covid-19 patients. On Tuesday, the MFDS announced that it gave emergency use approval for Actemra to treat seriously ill Covid-19 patients aged two or older. It is used for hospitalized Covid-19 patients receiving systemic corticosteroids who require supplemental oxygen. Actemra, developed by Chugai Pharmaceutical under the Roche Group, is an intravenous injectable autoimmune disease treatment. In Korea, the treatment obtained marketing approval for the treatment of rheumatoid arthritis. JW Pharmaceutical has the exclusive rights to develop and market Actemra in the local market. The emergency authorization came at the request of the Korea Disease Control and Prevention Agency (KDCA). The MFDS granted the permit for Actemra to prevent a shortage of Covid-19 treatments amid a spiking number of Covid-19 cases, it said. The MFDS reviewed Actemra using cases in other countries, clinical trial papers, and advice from infectious disease specialists. Then, it went through a review by the Public Health Risk Responding Healthcare Products Safety Management and Supply Committee and determined to grant the emergency license to Actemra. The treatment became reimbursable in March. With the latest approval for Actemra, JW Pharmaceutical came under the spotlight in the stock market. Shares of JW Pharmaceutical once shot up to a 52-week high at 31,900 won on Tuesday. On Tuesday morning, just before the announcement of the emergency authorization, Hanyang Securities released a report on JW Pharmaceutical to highlight the sales growth potential of Actemra. As the government decided not to supply the nation’s only Covid-19 treatment Regkirona anymore, marketing approval for Actemra is expected to have a substantial impact on the stock market,” Hanyang Securities said in the report. “Under the circumstance that Covid-19 cases shot up to hundreds of thousands daily, Actemra, which costs hundreds of thousands won per injection, could add earnings significantly.” An official at the MFDS cautioned against an outlook for an expanded supply of Actemra. “Actemra’s indication is different from Regkirona’s. Regkirona is to prevent mild and moderate Covid-19 patients from progressing to a serious disease, and Actemra is authorized to treat seriously ill patients,” the official said. Actemra suppresses the cytokine storm, so it will be effective to treat infection with the Omicron variant, too, he added.

JW Pharmaceutical Investments

1 Investments

JW Pharmaceutical has made 1 investments. Their latest investment was in SCL Therapeutics as part of their Seed on May 5, 2020.

CBI Logo

JW Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/8/2020

Seed

SCL Therapeutics

Yes

1

Date

5/8/2020

Round

Seed

Company

SCL Therapeutics

Amount

New?

Yes

Co-Investors

Sources

1

JW Pharmaceutical Acquisitions

2 Acquisitions

JW Pharmaceutical acquired 2 companies. Their latest acquisition was Euvipharm on September 04, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/4/2019

$99M

Acquired - II

6

10/29/2018

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/4/2019

10/29/2018

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired - II

Subscribe to see more

Sources

6

10

JW Pharmaceutical Partners & Customers

3 Partners and customers

JW Pharmaceutical has 3 strategic partners and customers. JW Pharmaceutical recently partnered with Kissei Pharmaceutical on June 6, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

6/28/2021

Licensor

Japan

1

8/24/2018

Licensee

Denmark

Subscribe to see more

Subscribe to see more

10

5/10/2017

Licensor

Japan

Subscribe to see more

Subscribe to see more

10

Date

6/28/2021

8/24/2018

5/10/2017

Type

Licensor

Licensee

Licensor

Business Partner

Country

Japan

Denmark

Japan

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

JW Pharmaceutical Team

1 Team Member

JW Pharmaceutical has 1 team member, including former Senior Vice President, ShinHong Kang.

Name

Work History

Title

Status

ShinHong Kang

Senior Vice President

Former

Name

ShinHong Kang

Work History

Title

Senior Vice President

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.